Health Care [ 3/12 ] | Biotechnology [ 13/75 ]
NASDAQ | Common Stock
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).
It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS.
Further, the company focuses on the development of product candidates for solid tumor programs.
It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products.
The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016.
Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 26 | -1.01 Decreased by -16.09% | -1.06 Increased by +4.72% |
| Nov 5, 25 | -0.99 Decreased by -106.25% | -0.96 Decreased by -3.13% |
| Aug 7, 25 | -0.94 Decreased by -84.31% | -1.02 Increased by +7.84% |
| May 8, 25 | -1.13 Decreased by -707.14% | -0.76 Decreased by -48.68% |
| Feb 27, 25 | -0.87 Decreased by -307.14% | -0.56 Decreased by -56.31% |
| Nov 8, 24 | -0.48 Increased by +40.74% | -0.34 Decreased by -41.18% |
| Aug 9, 24 | -0.51 Decreased by -2.00% | -0.52 Increased by +1.92% |
| May 9, 24 | -0.14 Increased by +75.86% | -0.51 Increased by +72.55% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 1.65 M Decreased by -89.17% | -58.11 M Decreased by -23.43% | Decreased by -3.51 K% Decreased by -1.04 K% |
| Sep 30, 25 | 4.95 M Decreased by -80.99% | -55.78 M Decreased by -115.65% | Decreased by -1.13 K% Decreased by -1.03 K% |
| Jun 30, 25 | 7.55 M Decreased by -72.41% | -52.77 M Decreased by -94.00% | Decreased by -698.58% Decreased by -603.26% |
| Mar 31, 25 | 8.13 M Decreased by -79.29% | -62.27 M Decreased by -765.10% | Decreased by -766.02% Decreased by -4.08 K% |
| Dec 31, 24 | 15.27 M Decreased by -75.83% | -47.08 M Decreased by -337.26% | Decreased by -308.40% Decreased by -1.08 K% |
| Sep 30, 24 | 26.03 M Increased by +74.03% | -25.87 M Increased by +34.24% | Decreased by -99.37% Increased by +62.21% |
| Jun 30, 24 | 27.38 M Increased by +91.47% | -27.20 M Decreased by -14.04% | Decreased by -99.34% Increased by +40.44% |
| Mar 31, 24 | 39.26 M Increased by +119.16% | -7.20 M Increased by +73.68% | Decreased by -18.34% Increased by +87.99% |